Feature | Lung Cancer | October 26, 2015

New Data May Help Physicians Better Understand Risk of Lung Cancer

Researchers confirm predictive capabilities of minimally invasive procedure that offers high accuracy for positive and negative diagnosis

University of Missouri, EBUS-TBFNA, lung cancer diagnosis

October 26, 2015 — University of Missouri researchers have developed a new scoring system for a common lung cancer diagnostic test that may help physicians better understand the risk for malignancy when evaluating patients.

Endobronchial ultrasound-guided transbronchial fine-needle aspiration, or EBUS-TBFNA, is a minimally invasive procedure often used for the initial diagnosis of many lung cancers. The test uses a thin, flexible scope that passes through the mouth and into the lungs to remove a small piece of tissue for evaluation. The test is commonly used because it can provide a rapid cancer diagnosis without the need for an invasive open procedure.

“The EBUS-TBFNA procedure is a diagnostic tool for lung cancer that yields proven results,” said Lester Layfield, M.D., professor and chair of the Department of Pathology and Anatomical Sciences at the MU School of Medicine and lead author of the study. “The test categorizes the results as ‘benign,’ ‘non-diagnostic,’ ‘atypical,’ ‘suspicious for malignancy’ or ‘malignant.’ Our goal with this study was to understand the risk of cancer associated with each category.”

Layfield’s research team evaluated information from 136 patients who received a diagnosis following the EBUS-TBFNA procedure. The same patients then had an open surgical procedure to confirm whether the tissue was cancerous or benign.

Layfield’s research team found that the EBUS-TBFNA tool provided an accurate positive diagnosis of lung cancer 84 percent of the time and an accurate negative diagnosis of lung cancer 68 percent of the time. The study also provided the research team with an estimation of malignancy risks for each category, which in the future could help doctors offer patients enhanced care and counseling, Layfield said.

The study, “Malignancy Risk Associated with the EBUS-FNA Diagnostic Categories Nondiagnostic, Benign, Atypical, Suspicious for Malignancy, and Malignant for Mediastinal Lymph Node Aspirate Specimens,” recently was published in the Journal of the American Society of Cytopathology.

For more information: www.jascyto.org

Related Content

Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
Zebra Medical Vision Unveils AI-Based Chest X-ray Research
News | Artificial Intelligence | June 08, 2018
June 8, 2018 — Zebra Medical Vision unveiled its Textray chest X-ray research, which will form the basis for a future
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
Researchers Use Radiomics to Overcome False Positives in Lung Cancer CT Screening
News | Advanced Visualization | May 29, 2018
A team of researchers including investigators from Mayo Clinic has identified a technology to address the problem of...
ACR Urges Stricter Adherence to Lung Cancer Screening Guidelines
News | Lung Cancer | May 21, 2018
A new statement from the American College of Radiology (ACR) asserts that provider non-compliance to lung cancer...
Matrix Analytics Announces Company Rebrand to Eon
News | Artificial Intelligence | May 16, 2018
Denver-based Matrix Analytics announced the company's rebrand to Eon. The rebrand marks the expansion of Eon's...
Body Vision Medical Receives FDA Clearance for LungVision Tool
Technology | Lung Cancer | May 09, 2018
Body Vision Medical received clearance from the U.S. Food and Drug Administration (FDA) to market their LungVision Tool...
El Camino Hospital Performs First U.S. Robotic Lung Cancer Bronchoscopy
News | Oncology Diagnostics | April 25, 2018
The interventional pulmonology team at the Taft Center for Clinical Research at El Camino Hospital in Mountain View,...
Overlay Init